Chinese Journal of Tissue Engineering Research ›› 2011, Vol. 15 ›› Issue (11): 2087-2090.doi: 10.3969/j.issn.1673-8225.2011.11.046

Previous Articles    

Effects of Gubenkeli capsule on matrix metallopeptidase 9 and tissue inhibitor of metalloproteinase1 levels in lung tissue of a rat model of chronic obstructive pulmonary disease

Yang Xiao-ping1, Zhou Zhao-shan2, Hu Hai-bo2, Wang Ping-li1, Yin Bin3   

  1. 1Clinical Department of Chinese and Western Integrative Medicine, Qingdao University Medical College, Qingdao   266021, Shandong Province, China
    2Department of Respiratory Medicine, Hiser Medical Group, Qingdao   266010, Shandong Province, China
    3Internal Medicine Department of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan 250014, Shandong Province, China
  • Received:2010-12-10 Revised:2011-02-15 Online:2011-03-12 Published:2011-03-12
  • Contact: Zhou Zhao-shan, Professor, Doctoral supervisor, Department of Respiratory Medicine, Hiser Medical Group, Qingdao 266010, Shandong Province, China sunnystar005@163. com
  • About author:Yang Xiao-ping★, Studying for master’s degree, Clinical Department of Chinese and Western Integrative Medicine, Qingdao University Medical College, Qingdao 266021, Shandong Province, China yangxiaoping8501@163.com
  • Supported by:

    Science and Technology Development Program of Qingdao, No. 05-2-NS-41*

PDF

377

Abstract:

BACKGROUND: The effectiveness and safety of traditional Chinese medicine treatment for chronic obstructive pulmonary disease (COPD) have been preliminarily approved by clinical practices.
OBJECTIVE: To investigate the effects of Gubenkeli capsule on the protein expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinase1 (TIMP-1) in lung tissue of COPD model rats.
METHODS: A total of 50 Wistar rats were randomly divided into five groups with 10 rats in each group: normal control, model, prednisone, Gubenkeli capsule-low dose, and Gubenkeli capsule-high dose. COPD rat models were established in all rats with the exception of the normal control rats by smoking and intratracheal instillation of LPS. At 29 days after COPD induction, rats from the prednisone, Gubenkeli capsule-low dose, Gubenkeli capsule-high dose groups were intragastrically administered prednisone (1.04 mg/kg per day), Gubenkeli capsule (0.4, 0.94 g/kg per day), once a day, to observer rat general conditions. Protein expression of MMP-9 and TIMP-1 in the lung tissue was detected by immunohistochemical methods. 
RESULTS AND CONCLUSION: Protein expression of MMP-9 and TIMP-1 in the lung tissue of COPD rats was significantly increased (P < 0.05). After drug intervention, the general conditions of COPD rats were greatly improved, and protein expression of MMP-9 and TIMP-1 in the lung tissue was decreased. Prednisone yields the strongest effects, followed by high-dose Gubenkeli capsule and low-dose Gubenkeli capsule. These findings demonstrate that Gubenkeli capsule alleviates the clinical manifestations of COPD model rats, improve airway remodeling, and correct the imbalance between prolease and antiprotease in a dose-response manner. 

CLC Number: